- Home
- CLPR vs CELU Comparison
CLPR vs CELU Comparison
Compare CLPR & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- CELU
- Stock Information
- Founded
- CLPR 2015
- CELU 2016
- Country
- CLPR United States
- CELU United States
- Employees
- CLPR N/A
- CELU N/A
- Industry
- CLPR Real Estate Investment Trusts
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- CLPR Real Estate
- CELU Health Care
- Exchange
- CLPR Nasdaq
- CELU Nasdaq
- Market Cap
- CLPR 67.0M
- CELU 56.9M
- IPO Year
- CLPR 2017
- CELU N/A
- Fundamental
- Price
- CLPR $3.94
- CELU $1.97
- Analyst Decision
- CLPR
- CELU Strong Buy
- Analyst Count
- CLPR 0
- CELU 1
- Target Price
- CLPR N/A
- CELU $6.00
- AVG Volume (30 Days)
- CLPR 59.3K
- CELU 167.1K
- Earning Date
- CLPR 11-06-2025
- CELU 12-05-2025
- Dividend Yield
- CLPR 9.64%
- CELU N/A
- EPS Growth
- CLPR N/A
- CELU N/A
- EPS
- CLPR N/A
- CELU N/A
- Revenue
- CLPR $154,103,000.00
- CELU $44,590,000.00
- Revenue This Year
- CLPR N/A
- CELU N/A
- Revenue Next Year
- CLPR N/A
- CELU $76.00
- P/E Ratio
- CLPR N/A
- CELU N/A
- Revenue Growth
- CLPR 7.69
- CELU 4.45
- 52 Week Low
- CLPR $3.39
- CELU $1.00
- 52 Week High
- CLPR $6.83
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- CLPR 44.31
- CELU 41.25
- Support Level
- CLPR $3.93
- CELU $1.94
- Resistance Level
- CLPR $4.24
- CELU $2.06
- Average True Range (ATR)
- CLPR 0.17
- CELU 0.12
- MACD
- CLPR -0.01
- CELU 0.02
- Stochastic Oscillator
- CLPR 29.64
- CELU 9.31
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.